InspireMD (NSPR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 3, 2025, in Tel Aviv, Israel, with voting available online or in person.
Shareholders are encouraged to review proxy materials and vote by June 2, 2025.
Voting matters and shareholder proposals
Election of two Class II directors, Michael Berman and Scott R. Ward, each for a three-year term.
Ratification of Kesselman & Kesselman (PwC) as independent auditors for the fiscal year ending December 31, 2025.
Board recommends voting in favor of all proposals.
Other business may be addressed as appropriate at the meeting.
Board of directors and corporate governance
Board structure includes staggered terms, with Class II directors up for election this cycle.
Partial view of Summaries dataset, powered by Quartr API
Latest events from InspireMD
- Q2 revenue up 5.4% with best-in-class trial results and $17.9M raised for U.S. launch.NSPR
Q2 20242 Feb 2026 - Q3 revenue up 16.3% to $1.81M; net loss widened; U.S. launch targeted for H1 2025.NSPR
Q3 202415 Jan 2026 - Q4 revenue up 10.7%, losses widen, and U.S. CGuard Prime launch expected in H1 2025.NSPR
Q4 202426 Dec 2025 - $200M shelf registration with $75M ATM equity offering to fund growth; dilution risk is significant.NSPR
Registration Filing16 Dec 2025 - Registers 16.6M shares for resale after $40.1M private placement and FDA approval in 2025.NSPR
Registration Filing16 Dec 2025 - CREST-2 data and CMS policy are driving rapid adoption of next-gen carotid stenting in the U.S.NSPR
Piper Sandler 37th Annual Healthcare Conference8 Dec 2025 - Annual meeting to elect directors and ratify auditor, with strong governance and compensation oversight.NSPR
Proxy Filing2 Dec 2025 - CMS reimbursement changes and strong clinical data position the company for rapid U.S. stent market growth.NSPR
24th Annual Needham Virtual Healthcare Conference28 Nov 2025 - Net loss widened on higher expenses as FDA approval and U.S. launch preparations continue.NSPR
Q1 202524 Nov 2025